Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

Phase 0 Not yet recruiting 20 enrolled State University of New York - Upstate Medical University

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.

Timeline

Start: 2026-05
Primary completion: 2027-03
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tafenoquine	Small molecule	300 mg	Oral

Indications

No indication recorded.